Merck & Co., Inc. $MRK Shares Sold by Convergence Financial LLC

Convergence Financial LLC decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 44.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,863 shares of the company’s stock after selling 8,693 shares during the period. Convergence Financial LLC’s holdings in Merck & Co., Inc. were worth $1,579,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Round Rock Advisors LLC boosted its stake in shares of Merck & Co., Inc. by 0.7% in the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock worth $1,272,000 after buying an additional 66 shares during the last quarter. Cypress Wealth Services LLC grew its holdings in shares of Merck & Co., Inc. by 0.5% in the third quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock worth $1,960,000 after acquiring an additional 69 shares during the period. Code Waechter LLC increased its position in Merck & Co., Inc. by 3.4% during the third quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock valued at $317,000 after acquiring an additional 71 shares during the last quarter. Cascade Financial Partners LLC increased its position in Merck & Co., Inc. by 0.5% during the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after acquiring an additional 80 shares during the last quarter. Finally, Somerset Trust Co increased its position in Merck & Co., Inc. by 0.9% during the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after acquiring an additional 81 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s KEYTRUDA reduced the risk of disease progression or death by 43% in a Phase 3 endometrial-cancer trial. The result strengthens the company’s oncology franchise and could support future label expansion and revenue growth. Merck’s KEYTRUDA Cuts Progression Risk By 43% In Phase 3 Endometrial Cancer Trial
• Positive Sentiment: Additional oncology readouts, including positive results from the Moderna-partnered melanoma vaccine and other cancer treatments, are providing fresh support for Merck’s pipeline and long-term growth prospects. Merck Gains Fresh Oncology Backing As Valuation Debate Heats Up
• Positive Sentiment: Broker commentary remains broadly constructive, with Barclays forecasting significant appreciation potential and other analysts highlighting KEYTRUDA demand and new-drug growth ahead of the earnings release. Barclays Forecasts Strong Price Appreciation for Merck
• Neutral Sentiment: Merck is scheduled to report third-quarter results before the market opens on October 29. Investors are focused on KEYTRUDA sales, full-year guidance and management’s outlook for the pipeline. Dear Merck Stock Fans, Mark Your Calendars for October 29
• Neutral Sentiment: The Moderna-Merck melanoma vaccine cut recurrence risk by 42% in a Phase 3 trial, but the outcome reportedly fell short of investor expectations, limiting its immediate effect on MRK. Merck and Moderna’s Cancer Vaccine Worked
• Negative Sentiment: Pre-earnings concerns include difficult year-over-year comparisons, declining earnings estimates, weaker Gardasil demand and looming patent exposure. These factors could offset strong KEYTRUDA performance and increase volatility around the report. Is Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings?

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $141.03 on Thursday. The stock has a 50-day simple moving average of $147.01 and a two-hundred day simple moving average of $126.31. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The firm has a market capitalization of $347.95 billion, a PE ratio of 112.83, a P/E/G ratio of 6.74 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the prior year, the business posted $2.13 earnings per share. The business’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts forecast that Merck & Co., Inc. will post 2.64 EPS for the current year.

Analysts Set New Price Targets

MRK has been the topic of several research reports. Leerink Partners raised their target price on Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Zacks Research lowered shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research report on Monday, October 19th. HSBC upped their price target on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Weiss Ratings upgraded shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. Finally, Jefferies Financial Group raised their price objective on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Seventeen research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $153.12.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares in the company, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard R. Deluca sold 20,784 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the sale, the executive vice president owned 134,703 shares in the company, valued at approximately $17,569,312.29. The trade was a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 in the last quarter. 0.17% of the stock is currently owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.